71258-18-9

Basic information

• Product Name: 1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride
• Synonyms: N-BENZYL-4-CYANO-4PHENYLPIPERIDINE HCL;1-N-BENZYL-4-CYANO-4-PHENYLPIPERIDINE HYDROCHLORIDE;1-BENZYL-4-CYANO-4-PHENYLPIPERIDINE HCL;4-PHENYL-1-(PHENYLMETHYL)-4-PIPERIDINECARBONITRILE HCL;1-benzyl-4-phenylpiperidine-4-carbonitrile monohydrochloride;1-N-Benzyl-4-Cyano-4-Phenylpiperidine Hydrochloride 1;1-N-Benzyl-4-cyano-4-phenylpiperidineHCl;1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride
• CAS NO: 71258-18-9
• Molecular Formula: C₁₉H₂₀N₂*ClH
• Molecular Weight: 312.84
• EINECS: 275-305-7
• Product Categories: API intermediates;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 71258-18-9.mol

Chemical Properties

• Melting Point: 257-261 °C
• Boiling Point: 430.4°C at 760 mmHg
• Flash Point: 184.3°C
• Appearance: /
• Vapor Pressure: 1.3E-07mmHg at 25°C
• CAS DataBase Reference: 1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride(71258-18-9)
• EPA Substance Registry System: 1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride(71258-18-9)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22
• Safety Statements: 45
• RIDADR: UN 3439 6.1/PG III
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 71258-18-9(Hazardous Substances Data)

Usage

Uses

1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride is used as a calcium channel blocker for its ability to regulate the flow of calcium ions through cellular membranes. This property makes it a valuable compound in the pharmaceutical industry for the development of medications targeting conditions related to calcium channel dysregulation.
Used in Pharmaceutical Industry:
1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride is used as an active pharmaceutical ingredient for the development of drugs aimed at treating cardiovascular diseases and other conditions where calcium channel modulation is beneficial. Its role as a calcium channel blocker helps in managing the contraction and relaxation of heart muscles and blood vessel dilation, which can be crucial in treating hypertension, angina, and certain arrhythmias.
Additionally, due to its chemical properties and potential applications, 1-Benzyl-4-cyano-4-phenylpiperidine hydrochloride may also be utilized in other industries for various purposes, such as in chemical research or as an intermediate in the synthesis of other compounds with specific therapeutic or industrial applications. However, the primary use highlighted in the provided materials is its application as a calcium channel blocker in the pharmaceutical industry.

InChI:InChI=1/C19H20N2/c20-16-19(18-9-5-2-6-10-18)11-13-21(14-12-19)15-17-7-3-1-4-8-17/h1-10H,11-15H2/p+1

Upstream product

• 56022-38-9 triethyl-hexadecyl-phosphonium; bromide 
• 140-29-4 phenylacetonitrile 
• 10429-82-0 N-benzyl-2-chloro-N-(2-chloroethyl)ethanamine hydrochloride 
• 55-51-6 N,N-bis(2-chloro-ethyl)-benzenemethanamine 

Downstream Products

• 19015-37-3 1-(phenylmethyl)-4-phenylpiperidine 
• 862287-81-8 1-benzyl-4-phenyl-4-(2H-tetrazol-5-yl)-piperidine 
• 3627-48-3 pethidinic acid 
• 1859-37-6 C-(1-methyl-4-phenyl-piperidin-4-yl)-methylamine 
• 3627-62-1 1-methyl-4-phenyl-piperidine-4-carbonitrile 
• 4220-10-4 (1-methyl-4-phenyl-piperidin-4-yl)-methanol 
• 57-42-1 pethidine 
• 40481-13-8 4-phenyl-4-cyanopiperidine 

Relevant articles and documents

Preparation method of 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride

The invention relates to the technical field of organic synthesis, in particular to a preparation method of 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride. The preparation method disclosed by the invention comprises the following steps of: (1) preparing benzyl diethanolamine by taking benzyl chloride and diethanolamine as raw materials; (2) preparing benzyl dichloroethylamine hydrochloride by taking benzyl diethanolamine and thionyl chloride as raw materials; and (3) preparing the 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride by taking the benzyl dichloroethylamine hydrochloride and the benzyl cyanide as raw materials. The preparation method disclosed by the invention is simple in process and suitable for industrial production, the HPLC content of the finally obtained 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride is greater than or equal to 98.0%, the total yield (based on diethanolamine) is greater than or equal to 89%, and the 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride has a very good market prospect.

NOVEL HETEROCYCLIC SUBSTITUTED PYRROLIDINE AMIDE DERIVATIVES

The present invention relates to novel heterocyclic substituted pyrrolidine amide derivatives of formula (1), and stereoisomers and pharmaceutically acceptable salts thereof and their use as tachykinin receptor antagonists. Such antagonists are useful in the treatment of tachykinin-mediated diseases and conditions disclosed herein including: asthma, cough, and bronchitis.

Process for preparing N,N-bis(2-hydroxyethyl)benzylamine and N,N-bis(2-chloroethyl)benzylamine

Improvements are shown in the successive preparations of N,N-bis(2-hydroxyethyl)benzylamine starting with benzyl chloride, its conversion to the corresponding N,N-bis(2-chloroethyl)benzylamine in substantially quantitative yield in toluene solution and using the latter by reaction with phenylacetonitrile in the presence of aqueous sodium hydroxide solution and a tetra-n-butylammonium salt, preferably the hydrogen sulfate, to produce improved over-all yields of up to over 75% (based on benzyl chloride) of 1-benzyl-4-cyano-4-phenylpiperidine hydrochloride, an intermediate for preparing meperidine.

Impurities in drugs II: meperidine and its formulations.

Three lots of meperidine hydrochloride, seven lots of meperidine tablets, and 41 lots of meperidine injectables were examined for impurities by TLC. Impurities found were ethyl 1-benzyl-4-phenyl-4-piperidinecarboxylate, methyl-4-piperidinecarboxylate, ethyl-4-phenyl-4-piperidinecarboxylate, and three unidentified compounds. Not all impurities were found in every lot of drug investigated, and none of the impurities exceeded a concentration of 1% of the meperidine present.